Validation of an immortalized human (hBMEC) in vitro blood-brain barrier model

Analytical and Bioanalytical Chemistry

Volumn 408, Issue 8, 2016, Pages 2095-2107

  Eigenmann, Daniela Elisabeth ^a   Jähne, Evelyn Andrea ^a   Smieško, Martin ^a   Hamburger, Matthias ^a   Oufir, Mouhssin ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

FDA EMA; hBMEC cell line; In vitro human blood brain barrier (BBB) model; Method validation; Permeability coefficient; UHPLC MS MS

Indexed keywords

CELL CULTURE; CONTROLLED DRUG DELIVERY; GLYCOPROTEINS; HYDRAULIC CONDUCTIVITY;

CELL LINES; FDA/EMA; HUMAN BLOODS; METHOD VALIDATIONS; U-HPLC-MS;

BLOOD;

BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL CULTURE TECHNIQUE; CELL LINE; COMPUTER SIMULATION; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; PHARMACOKINETICS; TANDEM MASS SPECTROMETRY; VASCULARIZATION;

BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL CULTURE TECHNIQUES; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; TANDEM MASS SPECTROMETRY;

EID: 84961286252     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-016-9313-6     Document Type: Article

References (48)

1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
2. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;2:3-14.
3. Di L, Rong H, Feng B. Demystifying brain penetration in central nervous system drug discovery. J Med Chem. 2013;56:2-12.
4. Deli MA. In: Lajtha A, Reith MEA, editors. Handb. Neurochem. Mol. Neurobiol. 3rd ed. Berlin Heidelberg: Springer Verlag; 2007. p. 29-55.
5. Tóth A, Veszelka S, Nakagawa S, Niwa M, Deli MA. Patented in vitro blood-brain barrier models in CNS drug discovery. Recent Pat CNS Drug Discov. 2011;6:107-18.
6. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: Basics and implications of the evolving new concept. Chem Biodivers. 2009;6:2030-49.
7. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54:253-63.
8. Helms HC, Waagepetersen HS, Nielsen CU, Brodin B. Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth. AAPS J. 2010;12:759-70.
9. Patabendige A, Skinner RA, Abbott NJ. Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance. Brain Res. 2012;1521:1-15.
10. Dehouck M-P, Meresse S, Delorme P, Fruchart J-C, Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem. 1990;54:1798-801.
11. Syvänen S, Lindhe Ö, Palner M, Kornum BR, Rahman O, Långström B, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37:635-43.
12. Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, Feng B, et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res. 2009;59:404-13.
13. Stins MF, Badger J, Kim KS. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog. 2001;30:19-28.
14. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-4.
15. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, Ohtsuki S, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol. 2010;225:519-28.
16. Maeda T, Sano Y, Abe M, Shimizu F, Kashiwamura Y, Ohtsuki S, et al. Establishment and characterization of spinal cord microvascular endothelial cell lines. Clin Exp Neurol. 2013;4:326-38.
17. Prudhomme JG, Sherman IW, Land KM, Moses AV, Stenglein S, Nelson JA. Studies of Plasmodium falciparum cytoadherence using immortalized human brain capillary endothelial cells. Int J Parasitol. 1996;26:647-55.
18. Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol. 2005;25:59-127.
19. Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS. 2013;10:33-50.
20. Guidance for Industry: Bioanalytical Method Validation, US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), May 2001.
21. Guideline on bioanalytical method validation, European Medicines Agency (EMEA/CHMP/EWP/192217/2009), London, 21 July 2011.
22. Wegener J, Abrams D, Willenbrink W, Galla H-J, Janshoff A. Automated multi-well device to measure transepithelial electrical resistances under physiological conditions. BioTechniques. 2004;37:590-7.
23. Siflinger-Birnboim A, del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB. Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol. 1987;132:111-7.
24. Dehouck M-P, Jolliet-Riant P, Breé F, Fruchart J-C, Cecchelli R, Tillement J-P. Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J Neurochem. 1992;58:1790-7.
25. Maestro, version 9.9, Schrödinger, LLC, New York, NY, 2014.
26. QikProp, version 4.1, Schrödinger, LLC, New York, NY, 2014.
27. Marvin 15.4.13.0, 2015, ChemAxon (http://www.chemaxon.com).
28. Bertrand CA, Durand DM, Saidel GM, Laboisse C, Hopfer U. System for dynamic measurements of membrane capacitance in intact epithelial monolayers. Biophys J. 1998;75:2743-56.
29. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16:1514-9.
30. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target. 1998;6:151-65.
31. Ji AJ, Jiang Z, Livson Y, Davis JA, Chu JX, Weng N. Challenges in urine bioanalytical assays: Overcoming nonspecific binding. Bioanalysis. 2010;2:1573-86.
32. Lippmann ES, Al-Ahmad A, Azarin SM, Palecek SP, Shusta EV. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. Sci Rep. 2014;4:1-10.
33. Sevin E, Dehouck L, Fabulas-da Costa A, Cecchelli R, Dehouck MP, Lundquist S, et al. Accelerated Caco-2 cell permeability model for drug discovery. J Pharmacol Toxicol Methods. 2013;68:334-9.
34. Hubatsch I, Ragnarsson EGE, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007;2:2111-9.
35. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther. 1997;283:574-80.
36. Salminen T, Pulli A, Taskinen J. Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal. 1997;15:469-77.
37. Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, Butina D. Correlation and prediction of a large blood-brain distribution data set- A n LFER study. Eur J Med Chem. 2001;36:719-30.
38. Usansky HH, Sinko PJ. Computation of LogBB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers. Pharm Res. 2003;20:390-6.
39. Rankovic Z. CNS drug design: Balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58:2584-608.
40. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737-50.
41. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies: Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev. 2000;45:283-94.
42. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck M-P. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharm Res. 2002;19:976-81.
43. Jähne EA, Eigenmann DE, Culot M, Cecchelli R, Walter FR, Deli MA, et al. Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. J Pharm Biomed Anal. 2014;98:235-46.
44. Zaugg J, Baburin I, Strommer B, Kim H-J, Hering S, Hamburger M. HPLC-based activity profiling: Discovery of piperine as a positive GABAA receptor modulator targeting a benzodiazepine-independent binding site. J Nat Prod. 2010;73:185-91.
45. Khom S, Strommer B, Schöffmann A, Hintersteiner J, Baburin I, Erker T, et al. GABAA receptor modulation by piperine and a non-TRPV1 activating derivative. Biochem Pharmacol. 2013;85:1827-36.
46. Schöffmann A, Wimmer L, Goldmann D, Khom S, Hintersteiner J, Baburin I, et al. Efficient modulation of γ-aminobutyric acid type A receptors by piperine derivatives. J Med Chem. 2014;57:5602-19.
47. Wimmer L, Schönbauer D, Pakfeifer P, Schöffmann A, Khom S, Hering S, et al. Developing piperine towards TRPV1 and GABAA receptor ligands-synthesis of piperine analogs via Heck-coupling of conjugated dienes. Org Biomol Chem. 2015;13:990-4.
48. McCall AL, Millington WR, Wurtman RJ. Blood-brain barrier transport of caffeine: Dose-related restriction of adenine transport. Life Sci. 1982;31:2709-15.